Melanoma vaccines: current R&D landscape, translational hurdles, and future outlook-a perspective drawn from 442
Canni Gao1, Xinxin Duan1, Leixuan Peng1
1Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background:
Melanoma, a highly malignant skin tumor with high metastatic propensity and poor survival in advanced stages, poses a major global public health challenge, as conventional treatments have notable limitations. Tumor immunotherapy, particularly cancer vaccines, has emerged as a promising approach by activating/regulating immune mechanisms to target cancer cells.
Methods:
This study systematically searched the Trialtrove database for interventional clinical trials of melanoma and cancer vaccines up to August 5, 2025. After screening via inclusion/exclusion criteria, 442 trials were analyzed, adhering to PRISMA guidelines with independent dual review for data reliability.
Results:
Trials were geographically concentrated in developed regions (69% in the US), with minimal participation from Asia, Africa, and Latin America. A "translational funnel effect" was observed: Phase I/I-II trials accounted for 63.6%, while Phase III trials only 6.1%, with a 22.9% termination rate. Peptide/recombinant protein vaccines (186 trials) and cellular vaccines (151 trials) were mainstream, with nucleic acid vaccines (58 trials) as a promising emerging platform. Combination therapy (227 trials, >50%), especially with immune checkpoint inhibitors (ICIs), dominated; adjuvants (e.g., IL-2, GM-CSF agonists) enhanced efficacy. Most trials focused on Stage III/IV patients (91.1%): key trials showed mRNA-4157 + pembrolizumab reduced recurrence/death risk by 49% in resected melanoma, and herpes simplex virus RP1 + nivolumab achieved 58.3% objective response rate (ORR) in ICI-resistant patients. Primary endpoints favored safety/immunogenicity (215/142 trials), with overall survival (OS, 33 trials) rarely used; academic institutions led funding (52.3%).
Conclusions:
Melanoma vaccines, especially in combination with ICIs and via personalized platforms, have significant potential. However, challenges include tumor heterogeneity, immunosuppressive tumor microenvironment (TME), inefficient delivery, geographical R&D imbalance, and low Phase III conversion. Interdisciplinary collaboration, international multicenter trials, optimized clinical design (e.g., early-stage patient enrollment), and policy support are needed to advance their clinical translation.
Insights
Melanoma cancer vaccines show promise, especially combined with immune checkpoint inhibitors. Challenges remain in clinical translation due to tumor heterogeneity and limited Phase III trials.
Area of Science:
- Oncology
- Immunology
- Clinical Trials
Background:
- Melanoma is a deadly skin cancer with limited treatment options.
- Cancer vaccines offer a promising immunotherapy approach for melanoma.
- Conventional treatments for advanced melanoma have significant limitations.
Purpose of the Study:
- To systematically review interventional clinical trials of melanoma and cancer vaccines.
- To analyze trends in vaccine development, trial phases, and therapeutic combinations.
- To identify challenges and future directions for melanoma vaccine clinical translation.
Main Methods:
- Systematic literature search of the Trialtrove database up to August 5, 2025.
- Analysis of 442 interventional clinical trials adhering to PRISMA guidelines.
- Independent dual review for data reliability and screening via inclusion/exclusion criteria.
Main Results:
- Most trials (63.6%) were in early phases (I/I-II), with a low Phase III conversion rate (6.1%).
- Peptide/protein (186) and cellular (151) vaccines were common; nucleic acid vaccines are emerging.
- Combination therapy, particularly with immune checkpoint inhibitors (ICIs), dominated (227 trials).
- Key trials demonstrated significant risk reduction (mRNA-4157 + pembrolizumab) and objective response rates (RP1 + nivolumab).
Conclusions:
- Melanoma vaccines, especially personalized ones combined with ICIs, hold significant therapeutic potential.
- Challenges include tumor heterogeneity, the immunosuppressive tumor microenvironment, and geographical R&D disparities.
- Advancing clinical translation requires interdisciplinary collaboration, international trials, and optimized trial designs.
More Related Videos
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:51Vaccinations
01:14Changes in Skin Color: Clinical Perspectives
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
01:12Statistical Software for Data Analysis and Clinical Trials
01:31Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...